HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Antagonism of pancuronium in renal failure: no recurarization.

Abstract
Neuromuscular transmission was measured using train-of-four stimulation, during and after anaesthesia, in 20 patients with end-stage renal failure. Neuromuscular blockade was provided with pancuronium in single doses of either 3 or 6 mg per 70 kg, and antagonized at 10% recovery with atropine and neostigmine 2.5 mg per 70 kg. Reversal was followed by progressive recovery of muscle twitch in every patient during the 3 h of the study. Recovery was more rapid after the smaller dose of pancuronium and was inversely correlated with the duration of blockade. It is concluded that, when pancuronium is antagonized with neostigmine in patients with renal failure, neuromuscular transmission recovers without evidence of recurarization. However, when large doses of pancuronium are antagonized with neostigmine 2.5 mg, recovery may be insufficient to ensure normal ventilatory function.
AuthorsD R Bevan, D Archer, F Donati, A Ferguson, B D Higgs
JournalBritish journal of anaesthesia (Br J Anaesth) Vol. 54 Issue 1 Pg. 63-8 (Jan 1982) ISSN: 0007-0912 [Print] England
PMID6275872 (Publication Type: Journal Article)
Chemical References
  • Neostigmine
  • Pancuronium
Topics
  • Adult
  • Aged
  • Female
  • Humans
  • Kidney Failure, Chronic (physiopathology)
  • Male
  • Middle Aged
  • Neostigmine (pharmacology)
  • Neuromuscular Junction (physiology)
  • Pancuronium (antagonists & inhibitors, pharmacology)
  • Synaptic Transmission (drug effects)
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: